Implications of Salmonella-induced nitric oxide (NO) for host defense and vaccines: NO, an antimicrobial, antitumor, immunosuppressive and immunoregulatory molecule

Microbes and Infection

Volumn 3, Issue 14-15, 2001, Pages 1223-1231

  Eisenstein, Toby K ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IL 12; Immunosuppression; Natural killer cells; Nitric oxide; Tumor immunity

Indexed keywords

BACTERIAL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; NITRIC OXIDE;

ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; MACROPHAGE; MICROBIAL ATTENUATION; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW;

SALMONELLA;

EID: 0035675136     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(01)01482-4     Document Type: Review

References (73)

1. Endothelium-derived relaxing and contracting factors
2. Macrophage cytotoxicity: Role for L-arginine deiminase and imino nitrogen oxidation to nitrite
3. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum
4. Three regulation mechanisms of nitric oxide synthase
5. Nitric oxide: A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells
6. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production
7. Macrophage activation: A riddle of immunological resistance
8. Activation of normal rabbit macrophage monolayers by supernatants of antigen-stimulated lymphocytes
9. L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells
10. Role of nitric oxide synthesis in macrophage antimicrobial activity
11. Resistance to intracellular infection
12. Remarks on the vaccination against typhoid fever
13. Controlled field trial in British Guiana school children of heat-killed phenolized and acetone-killed lyophilized typhoid vaccines
14. A controlled field trial of the effectiveness of phenol and alcohol typhoid vaccines
15. Results of the study of typhoid vaccines in four controlled field trials in the USSR
16. Typhoid Fever
17. 1A globulins in certain body fluids
18. Isolation and characterization of GalE mutant Ty21a of Salmonella typhi: A candidate strain for a live, oral typhoid vaccine
19. A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: Three-year results
20. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines
21. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein and avirulent and immunogenic
22. Construction of defined galE mutants of Salmonella for use as vaccines
23. Virulence and vaccine potential of phoP mutants of Salmonella typhimurium
24. Constitutive expression of the phoP regulon attenuates Salmonella virulence and survival within macrophages
25. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine
26. Safety, infectivity, immunogenicity and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in man
27. Cellular immunity induced by avirulent Salmonella in LPS-defective C3H/HeJ mice
28. Macrophage-mediated mitogenic suppression induced in mice of the C3H lineage by a vaccine strain of Salmonella typhimurium
29. Immunity to Salmonella typhimurium infection in C3H/HeJ and C3H/HeNCrlBR mice: Studies with an aromatic-dependent live S. typhimurium strain as a vaccine
30. Paradoxes of immunity and immunosuppression in Salmonella infection
31. Immunosuppression induced by attenuated Salmonella. Evidence for mediation by macrophage precursors
32. Immunosuppression induced by attenuated Salmonella: Effect of LPS responsiveness on development of suppression
33. Immunosuppression induced by attenuated Salmonella: Reversal by IL-4
34. Macrophage nitric oxide mediates immunosuppression in infectious inflammation
35. Suppressor macrophages
36. Molecular basis of "suppressor" macrophages. Arginine metabolism via the nitric oxide synthetase pathway
37. Regulation of macrophage functions by L-arginine
38. Nitric oxide: Physiology, pathophysiology, and pharmacology
39. Immunosuppression induced by nitric oxide and its inhibition by IL-4
40. Mechanism of suppression of nitric oxide synthase expression by interleukin-4 in primary mouse macrophages
41. Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation. Role of IFN-γ in the induction of the nitric oxide-synthesizing pathway
42. Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. Molecular basis for the synergy between interferon-γ and lipopolysaccharide
43. Immunosuppression and nitric oxide production induced by parenteral live Salmonella vaccines do not correlate with protective capacity: A phoP::Tn10 mutant does not suppress but does protect
44. Attenuated Salmonella vaccine-induced suppression of murine spleen cell responses to mitogen is mediated by macrophage nitric oxide: Quantitative aspects
45. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism
46. Synergism between tumor necrosis factor-α and interferon-γ on macrophage activation for the killing of intracellular Trypanosoma cruzi through a nitric oxide-dependent mechanism
47. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages
48. 2 and to L-arginine-dependent system in murine macrophages
49. Genetic and redox determinants of nitric oxide cytotoxicity in a Salmonellla typhimurium model
50. Evaluation of bacterial survival and phagocyte function with a fluorescence-based microplate assay
51. In vivo blockage of nitric oxide with aminoguanidine inhibits immunosuppression induced by an attenuated strain of Salmonella typhimurium, potentiates Salmonella infection, and inhibits macrophage and polymorphonuclear leukocyte influx into the spleen
52. Natural killer cells mediate protection induced by a Salmonella aro A mutant
53. Induction of interferon γ production by natural killer cell stimulatory factor: Characterization of the responding cells and synergy with other inducers
54. Interleukin-12 is critical for the induction of nitric oxide-mediated immunosuppression following vaccination of mice with attenuated Salmonella typhimurium
55. Salmonella typhimurium infection in mice induces nitric oxide-mediated immunosuppression through a natural killer cell-dependent pathway
56. Effect of IL-12 neutralization on host resistance and gamma-interferon production in mouse typhoid
57. Requirement for type 2 NO synthase for IL-12 signaling in innate immunity
58. Nitric oxide increased interleukin-4 expression in T lymphocytes
59. Induction of activated macrophages in C3H/HeJ mice by avirulent Salmonella
60. Immunotherapy of a plasmacytoma with attenuated salmonella
61. Nitric oxide mediates immunosuppression induced by Listeria monocytogenes: Quantitative studies
62. Macrophage nitric oxide mediates immunosuppression in infectious inflammation
63. Immunity to Salmonella infection in mice: Correlation of the duration and magnitude of protection to Salmonella infection afforded by various vaccines with antibody titers
64. Differences in delayed-type hypersensitivity responses in various mouse strains in the C3H lineage infected with Salmonella typhimurium, strain SL3235
65. Delayed-type hypersensitivity and immunity to Salmonella typhimurium
66. The origin and function of tumor-associated macrophages
67. Nitric-oxide-dependent systemic immunosuppression in animals with progressively growing malignant gliomas
68. Nitric oxide involvement in tumor-induced immunosuppression
69. Mucosal immune defense: The Salmonella typhimurium model
70. Immune responses and side effects of various Salmonella vaccines: Which one is best?
71. Immune suppression by recombinant interleukin (rIL)-12 involves interferon γ induction of nitric oxide synthase 2 (iNOS) activity: Inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect